Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POINT trial of NewGam dose-finding in CIDP
2009-017805-13Phase 2Terminated
- Sponsor
- Octapharma
- Start
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of subcuvia in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by Octapharma. Primary endpoint: Efficacy. Started Apr 2010; status: terminated.
02
Drugs
subcuvia
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2009-017805-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017805-13.